![Pfizer to Buy Medivation for $14 Billion, But Who Are the Real Winners?](https://evolution-bio.com/wp-content/uploads/2016/08/160822-pfizer-medivation-bio.jpg)
Pharmaceutical giants Pfizer are expanding their cancer portfolio through the $14B acquisition of California-based biopharmaceutical company Medivation. The acquisition follows two recent unsuccessful bids for Medivation by Sanofi, as well
![Will Mesoblast recover from Teva & Celgene setbacks?](https://evolution-bio.com/wp-content/uploads/2016/06/160628-mesoblast-biosci.jpg)
Australian Regenerative Medicine company Mesoblast recently suffered a significant financial setback in the ongoing development of MPC-150-IM, their experimental Phase III treatment for chronic heart failure, with their key US
![Celgene & Juno Therapeutics announce landmark deal for CAR-T Cancer Therapies](https://evolution-bio.com/wp-content/uploads/2016/04/150701-celgene-juno.jpg)
Celgene and Juno Therapeutics have announced a decade long collaboration to advance potentially groundbreaking immunotherapies for patients with cancer and autoimmune diseases. The two companies will leverage T cell therapeutic